Curaleaf Holdings Inc. - Asset Resilience Ratio
Curaleaf Holdings Inc. (CURA) has an Asset Resilience Ratio of 3.73% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check CURA PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2022–2024)
This chart shows how Curaleaf Holdings Inc.'s Asset Resilience Ratio has changed over time. See Curaleaf Holdings Inc. (CURA) net asset quality to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Curaleaf Holdings Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see CURA market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$107.49 Million | 3.73% |
| Short-term Investments | CA$0.00 | 0% |
| Total Liquid Assets | CA$107.49 Million | 3.73% |
Asset Resilience Insights
- Limited Liquidity: Curaleaf Holdings Inc. maintains only 3.73% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Curaleaf Holdings Inc. Industry Peers by Asset Resilience Ratio
Compare Curaleaf Holdings Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Aurobindo Pharma Limited
NSE:AUROPHARMA |
Drug Manufacturers - Specialty & Generic | 1.28% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 11.60% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026 |
Drug Manufacturers - Specialty & Generic | -0.89% |
|
Zhejiang Hisoar Pharmaceutical Co Ltd
SHE:002099 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Xeris Pharmaceuticals Inc
NASDAQ:XERS |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Procter & Gamble Health Limited
NSE:PGHL |
Drug Manufacturers - Specialty & Generic | 33.01% |
Annual Asset Resilience Ratio for Curaleaf Holdings Inc. (2022–2024)
The table below shows the annual Asset Resilience Ratio data for Curaleaf Holdings Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 3.64% | CA$107.23 Million ≈ $77.57 Million |
CA$2.95 Billion ≈ $2.13 Billion |
+0.66pp |
| 2023-12-31 | 2.98% | CA$92.29 Million ≈ $66.76 Million |
CA$3.10 Billion ≈ $2.24 Billion |
-1.80pp |
| 2022-12-31 | 4.78% | CA$163.18 Million ≈ $118.04 Million |
CA$3.41 Billion ≈ $2.47 Billion |
-- |
About Curaleaf Holdings Inc.
Curaleaf Holdings, Inc. produces and distributes cannabis products in the United States and internationally. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as distillate droppers, mints, topical balms and lotions, tinct… Read more